The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books
Dec 3, 2019 • 1h 12min
Ep58: Jigar Raythatha
Jigar Raythatha of Constellation Pharma on epigenetic drug development.
Nov 26, 2019 • 1h 21min
Ep57: John Alam
John Alam on Alzheimer's drug development.
Nov 13, 2019 • 1h 5min
Ep56: Tim Springer
Tim Springer of Harvard Medical School on his career in science and biotech.
Oct 29, 2019 • 1h 7min
Ep55: John Hawkins & Jim Geraghty
Discussion on the new Henri Termeer biography.
Oct 15, 2019 • 1h 6min
Ep54: Aoife Brennan
CEO of Synlogic on developing synthetic biology-based drugs.
Oct 1, 2019 • 1h 4min
Ep53: Phil Sharp
MIT biologist Phil Sharp on his early career.
Sep 18, 2019 • 46min
Ep52: Bruce Carter
Bruce Carter on developing a new tuberculosis drug.
Sep 3, 2019 • 1h 3min
Ep51: Ted Love
Ted Love of Global Blood Therapeutics on a new drug for sickle cell disease
Aug 20, 2019 • 1h 5min
Ep50: Joel Marcus
Joel Marcus, chairman of Alexandria Real Estate Equities, on building in biotech clusters.
Aug 8, 2019 • 1h 5min
Ep49: Janelle Anderson
Janelle Anderson on venture capital and off-the-shelf cell therapy at Century Therapeutics


